Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Teclison Ltd.
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Bristol-Myers Squibb
Pfizer
Alliance for Clinical Trials in Oncology
Pfizer
Bristol-Myers Squibb
Verastem, Inc.
Merus B.V.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
Bristol-Myers Squibb
PMV Pharmaceuticals, Inc
Mayo Clinic
Canadian Cancer Trials Group
Roswell Park Cancer Institute
Revolution Medicines, Inc.
Amgen
Pfizer
Tizona Therapeutics, Inc
Merck Sharp & Dohme LLC
Essen Biotech
Emory University
Emory University
Gazi University
VA Office of Research and Development
Eli Lilly and Company
VM Oncology, LLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Washington
Tango Therapeutics, Inc.
Krystal Biotech, Inc.
Daiichi Sankyo
The Christ Hospital
Latin American Cooperative Oncology Group
Institute of Cancer Research, United Kingdom
Mirati Therapeutics Inc.
Chinese University of Hong Kong
Fundación GECP
Vanderbilt-Ingram Cancer Center
Essen Biotech
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University